Instead of antibodies and aptamers, anti-EGFR affibodies, namely affinity reagents able to bind to a variety of targets [70], have been successfully used to functionalise microcapillaries and capture EVs harvested from non-small-cell lung cancer (NSCLC) cell lines H1975 in a label-free fashion [71]. Here, EGFR is linked to non-small cell lung carcinoma.